Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 6/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.34 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.34 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063841 | 0.82 | KIF11 (0.50) | KIF11 | |
| SCHEMBL17262489 | 0.78 | TSHR (0.39) | ALDH1A1TSHRKIF11 | |
| SCHEMBL221733 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TSHRKIF11CES2CES1 | |
| SCHEMBL29041310 | 0.74 | MEN1 (0.33) | — | |
| SCHEMBL192055 | 0.73 | ALDH1A1 (0.35) | ALDH1A1TSHRKIF11CES2CES1 | |
| SCHEMBL21268187 | 0.73 | KIF11 (0.43) | ALDH1A1TSHRKIF11CES2CES1 | |
| SCHEMBL16959676 | 0.73 | ALDH1A1 (0.35) | ALDH1A1TSHRKIF11CES2CES1 | |
| SCHEMBL192799 | 0.73 | ALDH1A1 (0.35) | ALDH1A1TSHRKIF11CES2CES1 | |
| SCHEMBL272417 | 0.73 | KIF11 (0.43) | ALDH1A1TSHRKIF11CES2CES1 | |
| SCHEMBL98163 | 0.73 | AHR (0.35) | ALDH1A1TSHRKIF11CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750894-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2024-04-03 | — | — | EP | claimed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | claimed |
| EP-3590941-B1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE-QUINAZOLINE AND -LINKED DIOXANE-QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | claimed |
| EP-3750893-B1 | DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-04-19 | — | — | EP | claimed |
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-26 | — | — | US | claimed |
| CN-113166116-B | Amido bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-12-27 | — | — | CN | claimed |
| EP-3901147-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-10-27 | — | — | EP | claimed |
| CN-113166116-A | Amido bridged heterocyclic compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-108698982-B | Fluorine atom-containing compound and use thereof | 日产化学工业株式会社 | 2021-07-16 | — | — | CN | claimed |
| EP-3172264-B1 | NOVEL POLYMERS CONTAINING GRAFTED BIS(SULFONYL)IMIDE SODIUM OR LITHIUM SALTS TO THE METHODS FOR THE PRODUCTION THEREOF, AND TO THE USES OF SAME AS ELECTROLYTES FOR BATTERIES | CDP INNOVATION (FR) | 2021-06-16 | — | — | EP | claimed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | claimed |
| EP-0900216-A1 | 1,3-OXAZIN-4-ONE DERIVATES AS HERBICIDES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION | RHONE-POULENC AGRICULTURE LTD. (GB) | 1999-03-10 | — | — | EP | claimed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | claimed |
| WO-1997040041-A1 | 1,3-OXAZIN-4-ONE DERIVATES AS HERBICIDES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION | RHONE-POULENC AGRICULTURE LTD. (GB) | 1997-10-30 | — | — | WO | claimed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | claimed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | claimed |
| US-4859228-A | Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones | ICI AMERICAS INC (US) | 1989-08-22 | — | — | US | claimed |
| EP-0300882-A2 | Novel 5-Aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones | ICI AMERICAS INC. (US) | 1989-01-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026425-A1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | RIPK1, RIPK3, RIPK4 | ALDH1A1 4164/4885TSHR 2607/4885KIF11 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.